Blog
Pearl IRB updated fee schedule in effect March 31, 2014
Please note that effective March 31, 2014, Pearl IRB has changed it’s fee schedule. To see pricing for your upcoming study, see our 2014 Fee Schedule. Please contact us at info@pearlirb.com for a price quote for Central IRB services, detailed pricing of your research...
New LinkedIn page for Pearl Pathways
Pearl Pathways is excited to publish our new LinkedIn Company Page. Please click this link to follow us. The Pearl Pathways LinkedIn page will enclose information about the company and the services we provide. We will also post the most important industry and company...
FDA adopt guidelines from ICH
Alexander Gaffney from raps.org has just released an article on regulators releasing the latest guideline on electronically transmitting individual case safety reports (ICSR) from the International Conference on Harmonisation’s (ICH). ICH is a pharmaceutical...
Next-generation gene technology’s role in clinical research
Pamela Scherer Mcleod from darkdaily.com wrote a very interesting article on how next-gen gene sequencing is affecting clinical research. Gene testing of patients enrolled in advanced cancer clinical trials may be able to supplement or even replace traditional...
Drug approval falls in 2013
Uk.reuters.com just released an article about the lackluster number of approved drugs by FDA in 2013. In 2013 only 27 were approved vs. 39 in 2012, which was the most since 1997. FDA attributed the large decrease to fewer applications in 2013 which was down from 41 to...